Published in Scand J Infect Dis on January 01, 1990
Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A (2014) 2.63
Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerg Infect Dis (1996) 2.51
Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun (2000) 2.34
Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev (1995) 1.95
Molecular population genetic analysis of emerged bacterial pathogens: selected insights. Emerg Infect Dis (1996) 1.94
Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol (2008) 1.81
Characterization and clonal distribution of four alleles of the speA gene encoding pyrogenic exotoxin A (scarlet fever toxin) in Streptococcus pyogenes. J Exp Med (1991) 1.66
Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. Emerg Infect Dis (1997) 1.49
Risk factors in the pathogenesis of invasive group A streptococcal infections: role of protective humoral immunity. Infect Immun (1999) 1.36
A comparison of group A streptococcal serotypes isolated from the upper respiratory tract in the USA and Thailand: implications. Bull World Health Organ (1992) 1.33
Evidence for niche adaptation in the genome of the bovine pathogen Streptococcus uberis. BMC Genomics (2009) 1.32
Clinical symptoms and signs in sore throat patients with large colony variant beta-haemolytic streptococci groups C or G versus group A. Br J Gen Pract (2005) 1.31
Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol (1992) 1.25
A globally disseminated M1 subclone of group A streptococci differs from other subclones by 70 kilobases of prophage DNA and capacity for high-frequency intracellular invasion. Infect Immun (1998) 1.19
Restricted association between biotypes and serotypes within group A streptococci. J Clin Microbiol (1994) 1.12
Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996. Eur J Clin Microbiol Infect Dis (2004) 1.09
Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun (2001) 1.07
Clonal diversity of Streptococcus pyogenes within some M-types revealed by multilocus enzyme electrophoresis. Epidemiol Infect (1994) 1.03
Invasive group a streptococcal infections, Israel. Emerg Infect Dis (2002) 1.02
A one-year study of streptococcal infections and their complications among Ethiopian children. Epidemiol Infect (1992) 1.00
Group A Streptococcal Sepsis. Curr Infect Dis Rep (2003) 1.00
Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. J Clin Microbiol (2009) 0.99
Clonality and diversity of the fish pathogen Lactococcus garvieae in Mediterranean countries. Appl Environ Microbiol (2004) 0.94
Transcriptome Remodeling Contributes to Epidemic Disease Caused by the Human Pathogen Streptococcus pyogenes. MBio (2016) 0.92
Pregnancy-related group a streptococcal infections: temporal relationships between bacterial acquisition, infection onset, clinical findings, and outcome. Clin Infect Dis (2013) 0.89
A cluster of cases of streptococcal necrotizing fasciitis in Gloucestershire. Epidemiol Infect (1995) 0.89
Group A Streptococcus: a re-emergent pathogen. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. CMAJ (1993) 0.86
Sequence type and emm type diversity in Streptococcus pyogenes isolates causing invasive disease in Norway between 1988 and 2003. J Clin Microbiol (2008) 0.81
Virulence related sequences; insights provided by comparative genomics of Streptococcus uberis of differing virulence. BMC Genomics (2015) 0.81
Inference of antibiotic resistance and virulence among diverse group A Streptococcus strains using emm sequencing and multilocus genotyping methods. PLoS One (2009) 0.80
Epidemiology of invasive group A streptococcal infections in Norway 2010-2014: A retrospective cohort study. Eur J Clin Microbiol Infect Dis (2016) 0.79
Life-threatening puerperal infection with group A streptococcus. J R Soc Med (1999) 0.78
Molecular characteristics of pharyngeal and invasive emm3 Streptococcus pyogenes strains from Norway, 1988-2003. Eur J Clin Microbiol Infect Dis (2009) 0.77
Puerperal fever and neonatal pleural empyema and bacteremia caused by group A streptococcus. Can J Infect Dis (1998) 0.75
Changing pattern of clinical illness in children with group A streptococcal bacteremia. Can J Infect Dis (1993) 0.75
Bacterial infection complicating varicella infection: A 10-year review of hospitalized children. Can J Infect Dis (1993) 0.75
Group A streptococcus--from basic science to clinical disease. West J Med (1996) 0.75
Management of early group A streptococcus fasciitis by imaging-guided percutaneous drainage. Radiol Case Rep (2015) 0.75
Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet (1991) 6.26
Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol (1986) 5.05
Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol (1994) 4.95
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA (1999) 3.69
Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet (1994) 3.16
Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol (1990) 2.58
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 2.44
Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986. J Infect Dis (1990) 1.96
The importance of blood volume cultured on detection of bacteraemia. Acta Pathol Microbiol Scand B (1981) 1.87
Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis. Antimicrob Agents Chemother (1993) 1.77
Some arguments on early hospital admission and treatment of suspected meningococcal disease cases. NIPH Ann (1990) 1.73
Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982. NIPH Ann (1983) 1.73
Injectional anthrax in a heroin skin-popper. Lancet (2000) 1.58
Polymerase chain reaction for case ascertainment of meningococcal meningitis: application to the cerebrospinal fluids collected in the course of the Norwegian meningococcal serogroup B protection trial. Scand J Infect Dis (1996) 1.55
Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981-1982. NIPH Ann (1983) 1.54
Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect (2000) 1.50
Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine (2003) 1.46
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun (1998) 1.46
The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis (1993) 1.42
Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun (1998) 1.42
Transmission of Neisseria meningitidis among asymptomatic military recruits and antibody analysis. Epidemiol Infect (1992) 1.39
Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol (1988) 1.34
A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb Pathog (1993) 1.25
Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect (1996) 1.20
Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen. J Clin Microbiol (1986) 1.19
Characteristics of serogroup A Neisseria meningitidis responsible for an epidemic in Ethiopia, 1988-89. Scand J Infect Dis (1990) 1.18
Detection of the phosphorylcholine epitope in streptococci, Haemophilus and pathogenic Neisseriae by immunoblotting. Microb Pathog (1997) 1.17
Outbreak of Shigella sonnei infection traced to imported iceberg lettuce. J Clin Microbiol (1995) 1.14
Evaluation of ten commercial heterophile antibody tests for infectious mononucleosis. Acta Pathol Microbiol Immunol Scand C (1985) 1.12
Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun (1995) 1.10
Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway. Clin Diagn Lab Immunol (1995) 1.10
Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants. Antimicrob Agents Chemother (2006) 1.04
The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci. Vaccine (1999) 1.04
Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann (1991) 1.02
Severity of meningococcal disease: assessment by factors and scores and implications for patient management. Rev Infect Dis (1991) 1.02
Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine (2003) 1.02
Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine (1999) 1.01
Hodgkin's disease in patients with previous infectious mononucleosis. Int J Cancer (1979) 1.01
A comparison of human and murine monoclonal IgGs specific for the P1.7 PorA protein of Neisseria meningitidis. Mol Immunol (1994) 0.97
Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect Immun (1999) 0.97
Emerging antibiotic resistance in Salmonella typhimurium in Norway. Epidemiol Infect (2000) 0.97
Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. NIPH Ann (1991) 0.96
Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann (1991) 0.96
Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb Pathog (1997) 0.95
Serogroup determination of Neisseria meningitidis by whole-cell ELISA, dot-blotting and agglutination. APMIS (1990) 0.95
Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol (1995) 0.94
Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis (1987) 0.92
The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand J Immunol (2004) 0.92
The occurrence and features of hemorrhagic skin lesions in 115 cases of systemic meningococcal disease. NIPH Ann (1983) 0.91
Monoclonal antibodies against Streptococcus pneumoniae detect epitopes on eubacterial ribosomal proteins L7/L12 and on streptococcal elongation factor Ts. Microbiology (1997) 0.91
Molecular epidemiology of macrolide-resistant isolates of Streptococcus pneumoniae collected from blood and respiratory specimens in Norway. J Clin Microbiol (2005) 0.90
Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand J Immunol (1998) 0.90
An epidemiological, clinical and microbiological follow-up study of incident meningococcal disease cases in Norway, winter 1981-1982. Material and epidemiology in the MenOPP project. NIPH Ann (1983) 0.90
Systemic pneumococcal disease in Norway 1995-2001: capsular serotypes and antimicrobial resistance. Epidemiol Infect (2004) 0.90
High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002. Epidemiol Infect (2006) 0.90
Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant. Dev Biol Stand (1998) 0.88
Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand J Infect Dis (2002) 0.87
Low occurrence of antibiotic resistance in Escherichia coli and staphylococci isolated from blood cultures in two Norwegian hospitals in 1991-92 and 1995-96. APMIS (1999) 0.87
Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods (1996) 0.87
Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH Ann (1991) 0.86
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand (1998) 0.86
A cluster of Legionnaires disease linked to an industrial plant in southeast Norway, June-July 2008. Euro Surveill (2008) 0.85
Risk of pneumococcal disease in individuals without a spleen. Lancet (1994) 0.85
Outbreak of meningococcal disease in western Norway due to a new serogroup C variant of the ET-5 clone: effect of vaccination and selective carriage eradication. Epidemiol Infect (1999) 0.84
Unbiased evidence on early treatment of suspected meningococcal disease. Rev Infect Dis (1990) 0.84
Antibiotic sensitivity still prevails in Norwegian blood culture isolates. Int J Antimicrob Agents (2001) 0.84
Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann (1991) 0.84
Colonization by Candida in children with cancer, children with cystic fibrosis, and healthy controls. Clin Microbiol Infect (2011) 0.83
Spectrum of disease in bacteraemic patients during a Streptococcus pyogenes serotype M-1 epidemic in Norway in 1988. Eur J Clin Microbiol Infect Dis (1992) 0.83
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun (2001) 0.83
Meningitis outbreaks and vaccination strategy. Trans R Soc Trop Med Hyg (1997) 0.82
Carriage of Streptococcus pneumoniae in healthy Norwegian children attending day-care centres. Eur J Clin Microbiol Infect Dis (2006) 0.82
Systemic group B streptococcal disease in neonates and young infants in Norway 1985-94. Acta Paediatr (1996) 0.81
Streptococcus pneumoniae heat shock protein 70 does not induce human antibody responses during infection. FEMS Immunol Med Microbiol (2000) 0.81
Outer membrane vesicles from Neisseria meningitidis: effects on cytokine production in human whole blood. Cytokine (2001) 0.80
Occurrence and clinical presentation of systemic pneumococcal infections in an unselected population in Oslo, Norway, between 1993 and 1997. Eur J Clin Microbiol Infect Dis (2002) 0.80
Immune responses to linear epitopes on the PorB protein of Neisseria meningitidis in patients with systemic meningococcal disease. Microbiology (1996) 0.80
Antibiotic resistance of pneumococci in Norway. Int J Antimicrob Agents (1998) 0.80
The diagnosis of meningococcal disease by culture. Some points of practical importance. NIPH Ann (1983) 0.80
Cross-reacting serum opsonins to meningococci after vaccination. J Infect Dis (1993) 0.79
[Treatment of uncomplicated gonorrhea in adults. New guidelines from the working group against gonorrhea]. Tidsskr Nor Laegeforen (1996) 0.78
Outer membrane vesicles from Neisseria meningitidis: effects on tissue factor and plasminogen activator inhibitor-2 production in human monocytes. Thromb Res (2001) 0.77
Molecular characteristics of pharyngeal and invasive emm3 Streptococcus pyogenes strains from Norway, 1988-2003. Eur J Clin Microbiol Infect Dis (2009) 0.77
Unexpected increase in case fatality of invasive group B streptococcal infections in infants in Norway, January-July 2006. Euro Surveill (2006) 0.76
Genetic aspects of complement component C8 in Norwegian meningococcal disease patients. Scand J Infect Dis (1990) 0.75
Citrinin, ochratoxin A and iron. Possible implications for their biological function and induction of nephropathy. Mycopathologia (1996) 0.75
Antimicrobial therapy and case fatality in meningococcal disease. Scand J Infect Dis (1987) 0.75
[The challenges of differential diagnosis of infections caused by beta-hemolytic streptococci]. Tidsskr Nor Laegeforen (1990) 0.75
[Infection problems in the leukopenia phase after autologous bone marrow transplantation]. Tidsskr Nor Laegeforen (1992) 0.75
Molecular characteristics and susceptibility to antibiotics of serogroup A Neisseria meningitidis strains isolated in Senegal in 1999. Scand J Infect Dis (2000) 0.75
Serotyping and bacteriophage typing of group B streptococci. NIPH Ann (1983) 0.75
Difficulties in diagnosing Brucella spondylitis. Scand J Infect Dis (2000) 0.75
The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily. Scand J Immunol (2011) 0.75
[Systemic meningococcal disease in the Norwegian Army]. Nord Med (1990) 0.75
[High incidence and mortality of systemic pneumococcal disease among persons without spleen]. Tidsskr Nor Laegeforen (1994) 0.75
[Excise the streptococci!]. Tidsskr Nor Laegeforen (1999) 0.75
Do HIV-seropositive patients become colonised with drug-resistant microorganisms? Eur J Clin Microbiol Infect Dis (2002) 0.75